Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 10/20 | 0.67 |
| ▸ | PDE5A | O76074 | 7/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16183658 | 0.93 | GBA1 (0.67) | GBA1PDE5APOLBKCNA5KCNH2 | |
| SCHEMBL16183655 | 0.92 | GBA1 (0.71) | GBA1PDE5AKCNA5KCNH2ALDH1A1 | |
| SCHEMBL14474517 | 0.91 | PDE5A (0.64) | GBA1PDE5APOLBKCNA5KCNH2 | |
| SCHEMBL16183656 | 0.91 | GBA1 (0.74) | GBA1PDE5APOLBALDH1A1LMNA | |
| SCHEMBL16183654 | 0.89 | GBA1 (0.72) | GBA1PDE5APOLBKCNA5KCNH2 | |
| SCHEMBL14474100 | 0.86 | PDE5A (0.61) | GBA1PDE5APOLBALDH1A1LMNA | |
| SCHEMBL16183660 | 0.84 | GBA1 (0.74) | GBA1PDE5APOLBALDH1A1LMNA | |
| SCHEMBL14727823 | 0.84 | PDE5A (0.62) | GBA1PDE5APOLBALDH1A1LMNA | |
| SCHEMBL14727599 | 0.83 | PDE5A (0.57) | GBA1PDE5APOLBALDH1A1LMNA | |
| SCHEMBL16183945 | 0.83 | PDE5A (0.62) | GBA1PDE5APOLBKCNA5KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-10-23 | — | — | US | disclosed |
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP2CA, PPP4C, PPP3CB | GBA1 1316/4885PDE5A 704/4885POLB 2309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.